NYSE:SNN

Smith & Nephew Competitors

$39.10
+0.30 (+0.77 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.85
Now: $39.10
$39.33
50-Day Range
$36.75
MA: $38.46
$40.81
52-Week Range
$34.29
Now: $39.10
$46.10
Volume849,908 shs
Average Volume429,310 shs
Market Capitalization$17.18 billion
P/E Ratio19.17
Dividend Yield2.34%
Beta0.7

Competitors

Smith & Nephew (NYSE:SNN) Vs. EW, ALGN, ZBH, STE, MSA, and AVNS

Should you be buying SNN stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Smith & Nephew, including Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), STERIS (STE), MSA Safety (MSA), and Avanos Medical (AVNS).

Edwards Lifesciences (NYSE:EW) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Edwards Lifesciences and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Smith & NephewN/AN/AN/A

Earnings and Valuation

This table compares Edwards Lifesciences and Smith & Nephew's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.34$1.05 billion$1.8646.37
Smith & Nephew$5.14 billion3.34$600 million$2.0419.17

Edwards Lifesciences has higher earnings, but lower revenue than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Edwards Lifesciences and Smith & Nephew, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
Smith & Nephew24602.33

Edwards Lifesciences currently has a consensus target price of $91.5417, indicating a potential upside of 6.14%. Smith & Nephew has a consensus target price of $47.1667, indicating a potential upside of 20.63%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Edwards Lifesciences.

Volatility and Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Institutional & Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.0% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Edwards Lifesciences beats Smith & Nephew on 11 of the 14 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Align Technology and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Smith & NephewN/AN/AN/A

Institutional and Insider Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 1.2% of Align Technology shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Align Technology and Smith & Nephew, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology13902.62
Smith & Nephew24602.33

Align Technology currently has a consensus price target of $501.3333, suggesting a potential downside of 15.73%. Smith & Nephew has a consensus price target of $47.1667, suggesting a potential upside of 20.63%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Align Technology.

Valuation & Earnings

This table compares Align Technology and Smith & Nephew's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion19.56$442.78 million$4.96119.95
Smith & Nephew$5.14 billion3.34$600 million$2.0419.17

Smith & Nephew has higher revenue and earnings than Align Technology. Smith & Nephew is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Smith & Nephew on 11 of the 14 factors compared between the two stocks.

Smith & Nephew (NYSE:SNN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares Smith & Nephew and Zimmer Biomet's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew$5.14 billion3.34$600 million$2.0419.17
Zimmer Biomet$7.98 billion4.39$1.13 billion$7.8721.39

Zimmer Biomet has higher revenue and earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Smith & Nephew and Zimmer Biomet, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Smith & Nephew24602.33
Zimmer Biomet131632.91

Smith & Nephew presently has a consensus target price of $47.1667, suggesting a potential upside of 20.63%. Zimmer Biomet has a consensus target price of $165.5909, suggesting a potential downside of 1.62%. Given Smith & Nephew's higher possible upside, equities research analysts clearly believe Smith & Nephew is more favorable than Zimmer Biomet.

Profitability

This table compares Smith & Nephew and Zimmer Biomet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Smith & NephewN/AN/AN/A
Zimmer Biomet0.52%10.07%4.93%

Dividends

Smith & Nephew pays an annual dividend of $0.90 per share and has a dividend yield of 2.3%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. Smith & Nephew pays out 44.1% of its earnings in the form of a dividend. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Smith & Nephew has increased its dividend for 1 consecutive years and Zimmer Biomet has increased its dividend for 1 consecutive years.

Risk & Volatility

Smith & Nephew has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

8.9% of Smith & Nephew shares are held by institutional investors. Comparatively, 87.2% of Zimmer Biomet shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Comparatively, 0.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Zimmer Biomet beats Smith & Nephew on 14 of the 17 factors compared between the two stocks.

STERIS (NYSE:STE) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

90.0% of STERIS shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 1.2% of STERIS shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares STERIS and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STERIS13.97%14.44%9.32%
Smith & NephewN/AN/AN/A

Earnings and Valuation

This table compares STERIS and Smith & Nephew's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$3.03 billion5.77$407.61 million$5.6436.32
Smith & Nephew$5.14 billion3.34$600 million$2.0419.17

Smith & Nephew has higher revenue and earnings than STERIS. Smith & Nephew is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for STERIS and Smith & Nephew, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STERIS02302.60
Smith & Nephew24602.33

STERIS presently has a consensus target price of $214.25, suggesting a potential upside of 4.59%. Smith & Nephew has a consensus target price of $47.1667, suggesting a potential upside of 20.63%. Given Smith & Nephew's higher possible upside, analysts plainly believe Smith & Nephew is more favorable than STERIS.

Dividends

STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Smith & Nephew pays an annual dividend of $0.90 per share and has a dividend yield of 2.3%. STERIS pays out 28.4% of its earnings in the form of a dividend. Smith & Nephew pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has raised its dividend for 15 consecutive years and Smith & Nephew has raised its dividend for 1 consecutive years.

Volatility & Risk

STERIS has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

STERIS beats Smith & Nephew on 11 of the 17 factors compared between the two stocks.

MSA Safety (NYSE:MSA) and Smith & Nephew (NYSE:SNN) are both industrial products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Dividends

MSA Safety pays an annual dividend of $1.72 per share and has a dividend yield of 1.1%. Smith & Nephew pays an annual dividend of $0.90 per share and has a dividend yield of 2.3%. MSA Safety pays out 35.8% of its earnings in the form of a dividend. Smith & Nephew pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. MSA Safety has increased its dividend for 11 consecutive years and Smith & Nephew has increased its dividend for 1 consecutive years.

Earnings & Valuation

This table compares MSA Safety and Smith & Nephew's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MSA Safety$1.40 billion4.25$136.44 million$4.8031.77
Smith & Nephew$5.14 billion3.34$600 million$2.0419.17

Smith & Nephew has higher revenue and earnings than MSA Safety. Smith & Nephew is trading at a lower price-to-earnings ratio than MSA Safety, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for MSA Safety and Smith & Nephew, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MSA Safety01202.67
Smith & Nephew24602.33

MSA Safety presently has a consensus target price of $151.50, suggesting a potential downside of 0.65%. Smith & Nephew has a consensus target price of $47.1667, suggesting a potential upside of 20.63%. Given Smith & Nephew's higher probable upside, analysts clearly believe Smith & Nephew is more favorable than MSA Safety.

Institutional and Insider Ownership

77.2% of MSA Safety shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 7.0% of MSA Safety shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares MSA Safety and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MSA Safety10.40%23.96%10.13%
Smith & NephewN/AN/AN/A

Volatility and Risk

MSA Safety has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Summary

MSA Safety beats Smith & Nephew on 12 of the 17 factors compared between the two stocks.

Avanos Medical (NYSE:AVNS) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Volatility and Risk

Avanos Medical has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Avanos Medical and Smith & Nephew, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avanos Medical10102.00
Smith & Nephew24602.33

Avanos Medical presently has a consensus target price of $50.00, indicating a potential upside of 10.25%. Smith & Nephew has a consensus target price of $47.1667, indicating a potential upside of 20.63%. Given Smith & Nephew's stronger consensus rating and higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Avanos Medical.

Profitability

This table compares Avanos Medical and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avanos Medical1.93%3.20%2.28%
Smith & NephewN/AN/AN/A

Insider and Institutional Ownership

94.8% of Avanos Medical shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 1.5% of Avanos Medical shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Avanos Medical and Smith & Nephew's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avanos Medical$697.60 million3.12$-45,900,000.00$1.0742.38
Smith & Nephew$5.14 billion3.34$600 million$2.0419.17

Smith & Nephew has higher revenue and earnings than Avanos Medical. Smith & Nephew is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.


Smith & Nephew Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$86.25+0.2%$53.65 billion$4.35 billion69.00Upcoming Earnings
Insider Selling
Align Technology logo
ALGN
Align Technology
1.9$594.93+0.1%$47.08 billion$2.41 billion27.07
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$168.31+0.1%$35.06 billion$7.98 billion1,052.00
STERIS logo
STE
STERIS
2.1$204.84+0.9%$17.48 billion$3.03 billion41.55Increase in Short Interest
MSA Safety logo
MSA
MSA Safety
2.1$152.49+0.3%$5.96 billion$1.40 billion43.20
Avanos Medical logo
AVNS
Avanos Medical
1.5$45.35+1.8%$2.18 billion$697.60 million156.38
Eargo logo
EAR
Eargo
1.0$48.00+3.1%$1.84 billionN/A0.00Increase in Short Interest
Lockup Expiration
Establishment Labs logo
ESTA
Establishment Labs
1.2$70.50+3.0%$1.66 billion$89.57 million-41.72Decrease in Short Interest
Inogen logo
INGN
Inogen
1.2$62.70+5.1%$1.40 billion$361.94 million-696.59
Sientra logo
SIEN
Sientra
1.6$7.15+2.4%$409.50 million$83.70 million-4.02Increase in Short Interest
Invacare logo
IVC
Invacare
1.6$8.49+1.4%$292.26 million$927.96 million-6.90Analyst Downgrade
SMTI
Sanara MedTech
0.8$29.75+0.2%$226.61 million$11.77 million-23.06Decrease in Short Interest
Lakeland Industries logo
LAKE
Lakeland Industries
1.6$27.78+1.5%$222.80 million$107.81 million7.89
Surgalign logo
SRGA
Surgalign
1.7$1.87+2.1%$206.20 million$308.38 million-1.04Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.87+2.1%$206.20 million$308.38 million-1.04Increase in Short Interest
Conformis logo
CFMS
Conformis
1.3$0.84+0.0%$152.55 million$77.43 million-2.46
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.97+2.0%$90.80 million$4.87 million-1.56Decrease in Short Interest
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$14.52+1.2%$82.33 million$2.32 million-7.26Analyst Downgrade
Decrease in Short Interest
News Coverage
Gap Up
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.18+10.2%$57.58 million$1.41 million-0.19
AHPI
Allied Healthcare Products
0.5$4.46+1.3%$17.89 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.95+5.3%$12.72 million$530,000.00-1.58Decrease in Short Interest
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.